---

Advancing Diagnostic Confidence in Leptomeningeal Metastases

In leptomeningeal metastases (LM) care, timely and accurate diagnostic information can make a meaningful difference in how physicians evaluate and manage patients with suspected central nervous system (CNS) involvement.

From a single CSF sample, the CNSide Diagnostics® Cerebrospinal Fluid (CSF) Assay Platform was developed to help provide actionable insights to analyze if there is potential for the disease known as LM. This offers physicians additional data that may support the diagnosis and ongoing monitoring of leptomeningeal metastases.

As neuro-oncology continues to evolve, advanced diagnostic technologies are becoming increasingly important in helping clinicians move from uncertainty toward greater diagnostic clarity.

---

Understanding the Challenges of Leptomeningeal Metastases Diagnosis

Leptomeningeal metastases occur when cancer spreads to the membranes surrounding the brain and spinal cord and into the cerebrospinal fluid.

LM is often associated with:

• Complex neurologic symptoms
• Rapid disease progression
• Diagnostic uncertainty
• Significant clinical management challenges

Traditional diagnostic methods, including standard CSF cytology, may present limitations in sensitivity, particularly when tumor cell burden is low. Because of this, clinicians frequently rely on multiple data sources when evaluating patients with suspected LM.

Improving access to highly sensitive and comprehensive CSF-based diagnostic information remains an important focus in neuro-oncology.

---

How CNSide® Provides Actionable CSF Insights

The CNSide® CSF Assay Platform is designed to analyze tumor cells present in cerebrospinal fluid and provide detailed diagnostic information from a single sample.

The platform is intended to help clinicians:

• Confirm or rule out leptomeningeal metastases
• Obtain additional tumor-related insights
• Monitor disease progression through serial testing
• Evaluate treatment response over time
• Support broader clinical decision-making

By leveraging advanced tumor cell detection and characterization technologies, CNSide® aims to provide a more comprehensive picture of CNS disease involvement.

---

Enhanced Sensitivity Compared with Traditional CSF Cytology

Clinical studies evaluating CNSide® have demonstrated enhanced sensitivity compared with traditional CSF cytology in detecting tumor cells associated with leptomeningeal metastases.

In addition, studies have shown that CNSide® data informed clinical decisions in more than 90% of evaluated cases, highlighting the growing importance of advanced CSF diagnostics in modern neuro-oncology workflows.

These findings reinforce the potential value of integrating advanced diagnostic platforms into the evaluation and management of patients with suspected LM.

---

The Importance of Serial Testing in LM Management

Leptomeningeal metastases management often requires ongoing assessment throughout the course of treatment.

Serial CSF testing may provide clinicians with additional opportunities to:

• Monitor changes in tumor cell burden
• Track disease progression
• Assess therapeutic response
• Support evolving treatment strategies

As precision medicine continues to expand across oncology, longitudinal disease monitoring is becoming increasingly important in helping clinicians personalize patient care.

---

Moving from Uncertainty to Greater Diagnostic Clarity

For physicians managing complex neuro-oncology cases, access to highly sensitive and actionable CSF-based tumor data may help support more informed diagnostic and treatment decisions.

CNSide® is focused on helping clinicians navigate the challenges of leptomeningeal metastases by providing advanced diagnostic insights designed specifically for CNS metastatic disease.

As awareness of LM grows and diagnostic technologies continue to advance, CSF-based platforms like CNSide® are helping shape the future of neuro-oncology diagnostics.

Interested in learning more or ordering a CSF Assay test from our lab? Contact CNSide Diagnostics

---

About CNSide® Diagnostics

CNSide® is a proprietary diagnostic platform designed to detect and characterize tumor cells in cerebrospinal fluid (CSF) from patients with leptomeningeal metastases. The platform combines advanced technologies to support enhanced diagnostic insights and help address unmet needs in neuro-oncology.nsights and help address unmet needs in neuro-oncology.